WO2005007137A2 - Ambroxolhaltige tabletten - Google Patents
Ambroxolhaltige tabletten Download PDFInfo
- Publication number
- WO2005007137A2 WO2005007137A2 PCT/EP2004/007849 EP2004007849W WO2005007137A2 WO 2005007137 A2 WO2005007137 A2 WO 2005007137A2 EP 2004007849 W EP2004007849 W EP 2004007849W WO 2005007137 A2 WO2005007137 A2 WO 2005007137A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- tablet according
- ambroxol
- core
- cellulose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to the active ingredient ambroxol or to a tablet containing its pharmacologically acceptable salts, the ambroxol content per tablet being in a range from 250 to 1000 mg.
- Ambroxol (trans-4- (2-amino-3,5-dibromobenzylamino) cyclohexanol) is used as an expectorant in the form of syrup, juice and tablets, and as a local anesthetic in the form of a lozenge. Ambroxol also shows good effects in the treatment of chronic pain, especially at a daily dose of 500 mg or more.
- Ambroxol-containing tablets with an ambroxol content of up to 75 mg / tablet are known in the prior art.
- Ambroxol is administered as a high-dose formulation in the form of a 1000 mg / ml solution for injection for the prophylaxis of respiratory distress syndrome and for prenatal lung maturation.
- a patient For the treatment of diseases, for example chronic pain, which require a daily dose of ambroxol of 500 mg day or more, a patient would take at least six tablets of the 75 mg tablets previously available. In order to allow the patient an acceptable intake schedule, several tablets would have to be replaced by an increased single dose per tablet. The production of a tablet with an increased dosage is problematic. For example, attention must be paid to the tablet size so that the patient's reluctance to take a tablet that is too large is avoided.
- the invention relates to a tablet containing a core and a film covering this core, characterized in that the core has a
- Ambroxol content of 150 to 1200 mg contains ambroxol.
- a tablet is preferred, the core containing an ambroxol content of 500 to 1000 mg, preferably 750 to 800 mg, of ambroxol.
- a tablet in which the core one or more of the fillers selected from the group consisting of pregelatinized starch, microcrystalline cellulose, hydroxypropyl cellulose, cellulose, mannitol, erythritol, lactose, sucrose, calcium hydrogen phosphate, calcium carbonate, corn starch, sorbitol and xylitol, preferably pregelatinized Starch, microcrystalline cellulose, hydroxypropyl cellulose with low substitution, mannitol, erythritol and lactose, particularly preferably pregelatinized starch, microcrystalline cellulose and hydroxypropyl cellulose with low substitution.
- a tablet in which the core is one or more is particularly preferred
- Disintegration promoters selected from the group consisting of croscarmellose sodium (cellulose carboxymethylether sodium salt, crosslinked), sodium starch glycolate, crosslinked polyvinylpyrrolidone (crospovidone), corn starch, microcrystalline cellulose, pregelatinized starch, and hydroxypropyl cellulose low substituted, preferably crospovidone, croscarmellose sodium and sodium starch glycolate, more preferably croscarmellose sodium and crospovidone , contains.
- a tablet in which the core is one or more binders selected from the group consisting of polyvinylpyrrolidone (Povidone), copolymers of vinylpyrrolidone with other vinyl derivatives (Copovidone), hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylcellulose, and starch, preferably povidethylcellulose, hydroxypropyl Copovidone, particularly preferably Polvidone and Copovidone, contains.
- binders selected from the group consisting of polyvinylpyrrolidone (Povidone), copolymers of vinylpyrrolidone with other vinyl derivatives (Copovidone), hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylcellulose, and starch, preferably povidethylcellulose, hydroxypropyl Copovidone, particularly preferably Polvidone and Copovidone, contains.
- the film coating contains auxiliaries selected from the group consisting of talc, titanium dioxide, hydroxypropylmethyl cellulose and polyoxyethylene glycol.
- the film coating can contain one or more synthetic or natural, pharmaceutically acceptable dyes, preferably iron oxide,
- a tablet in which the weight fraction of ambroxol in relation to the total mass of the core is 30-90% by weight (% by weight), preferably 40-90% by weight, particularly preferably 60-70% by weight ,
- a tablet in which the proportion by weight of the film in relation to the total mass of the tablet is 2 to 4% by weight, preferably 2 to 3% by weight.
- Another object of the invention is a process for producing the tablet according to the invention, the following process steps a) to f) being carried out in the order given:
- Another object of the invention is the use of the tablet according to the invention for the manufacture of a medicament for the treatment of chronic pain, preferably chronic neuropathic or chronic nociceptive pain, particularly preferably chronic neuropathic pain.
- Another object of the invention is the use of the tablet according to the invention for the manufacture of a medicament for the treatment of tinnitus.
- Another object of the invention is the use of the tablet according to the invention for the manufacture of a medicament for the treatment of acute pain, preferably surgery pain, toothache, pain after trauma, pain after burns, pain after stroke or heart attack, pain with cramps or pain with colic.
- Another object of the invention is the use of the tablet according to the invention for the manufacture of a medicament for the treatment of epilepsy.
- the proportion of the fillers in relation to the entire core of the tablet according to the invention is in a range from 1 to 70% by weight, preferably in a range from 5 to 50% by weight, particularly preferably in a range from 20 to 30% by weight.
- the proportion of the binders in relation to the entire core of the tablet according to the invention is in a range from 1 to 20% by weight, preferably in a range from 2 to 10% by weight, particularly preferably in a range from 4 to 6% by weight. -%.
- the proportion of the disintegrators in relation to the entire core of the tablet according to the invention is in a range from 1 to 20% by weight, preferably in a range from 2 to 10% by weight, particularly preferably in a range from 3 to 5% by weight.
- the proportion of the lubricants in relation to the entire core of the tablet according to the invention is in a range from 0.25 to 6% by weight, preferably in a range from 0.4 to 4% by weight, particularly preferably in a range from 0 , 5 to 2 wt .-%.
- ambroxol means both the base ambroxol and its solvates or hydrates. Ambroxol contents in mg or% by weight refer to the base of the ambroxol.
- Acids suitable for salt formation of ambroxol are, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, oxalic acid, malonic acid, fumaric acid, maleic acid, tartaric acid, citric acid, ascorbic acid and methanesulfonic acid, preferably hydrochloric acid.
- the film tablet according to the invention can be produced, for example, as described below.
- Ambroxol or one of its pharmacologically acceptable salts is premixed with a binder and optionally other of the auxiliaries described above.
- the active ingredient premix obtained therefrom is then granulated in a fluidized bed granulator with an aqueous binder solution.
- Alternative granulation methods with aqueous binder solutions are wet granulation in an intensive mixer or one-pot granulator or moisture extrusion followed by sieving, drying and dry sieving of the granules.
- the dried granules are sieved, preferably using a 0.8 mm Comil sieve. Further excipients such as disintegration promoters are added to the active ingredient granules and then mixed, for example, in a free-fall mixer. After the mixing process has ended, the active ingredient / excipient mixture obtained in this way is subsequently converted into the inventive tablets on a suitable tablet press Compressed film-coated tablet cores with the desired target weight and suitable shape, size and breaking strength.
- the components of the film coating which are required and optional are taken up in a suitable solvent.
- a suitable solvent According to the invention, water is preferably used as the solvent.
- Iron oxide red 0.800 0.062 2.000
- Hydroxypropyl cellulose low subst. 100,000 10,000
- Hydroxypropylmethyl cellulose 15,000 1,500 50,000
- Iron oxide red 0.600 0.060 2.000
- Ambroxol film-coated tablet 1000 mg mg /% per% of the tablet tablet film 1096.427 84.341
- Iron oxide red q.s.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04763241A EP1648423A2 (de) | 2003-07-16 | 2004-07-15 | Ambroxolhaltige tabletten |
CA002532485A CA2532485A1 (en) | 2003-07-16 | 2004-07-15 | Tablets containing ambroxol |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10332458.5 | 2003-07-16 | ||
DE10332458 | 2003-07-16 | ||
DE10360086.8 | 2003-12-20 | ||
DE10360086A DE10360086A1 (de) | 2003-07-16 | 2003-12-20 | Ambroxolhaltige Tabletten |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2005007137A2 true WO2005007137A2 (de) | 2005-01-27 |
WO2005007137A3 WO2005007137A3 (de) | 2005-04-28 |
WO2005007137A8 WO2005007137A8 (de) | 2006-09-21 |
Family
ID=34081653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/007849 WO2005007137A2 (de) | 2003-07-16 | 2004-07-15 | Ambroxolhaltige tabletten |
Country Status (4)
Country | Link |
---|---|
US (1) | US20050027012A1 (de) |
EP (1) | EP1648423A2 (de) |
CA (1) | CA2532485A1 (de) |
WO (1) | WO2005007137A2 (de) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9493462B2 (en) | 2006-05-04 | 2016-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9556175B2 (en) | 2002-08-21 | 2017-01-31 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions |
US9603851B2 (en) | 2010-05-05 | 2017-03-28 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9751855B2 (en) | 2004-11-05 | 2017-09-05 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8206742B2 (en) * | 2006-01-12 | 2012-06-26 | Wockhardt Ltd. | Sustained release compositions of alfuzosin |
FR2900823B1 (fr) * | 2006-05-15 | 2009-02-13 | Bioprojet Soc Civ Ile | Nouvelle forme d'administration du racecadotril. |
TW201521794A (zh) * | 2013-11-12 | 2015-06-16 | Daiichi Sankyo Co Ltd | 錠劑 |
CN108113971B (zh) * | 2016-11-28 | 2021-12-28 | 北京科信必成医药科技发展有限公司 | 一种盐酸氨溴索掩味制剂及其制备方法 |
CN112745251B (zh) * | 2019-10-31 | 2023-10-27 | 华创合成制药股份有限公司 | 一种治疗祛痰化合物及其制备方法和用途 |
CN112773769B (zh) * | 2019-11-07 | 2022-11-15 | 烟台东诚药业集团股份有限公司 | 一种盐酸氨溴索分散片及其制法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1178034A (en) * | 1966-05-10 | 1970-01-14 | Thomae Gmbh Dr K | Hydroxy-Cyclohexylamines |
EP0138020A2 (de) * | 1983-09-17 | 1985-04-24 | Dr. Karl Thomae GmbH | Antiadhäsive Prophylactica und Arzneimittel enthaltend ein sekretolytisch wirksames Benzylaminderivat |
WO2003061642A1 (de) * | 2002-01-25 | 2003-07-31 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Verwendung von ambroxol zur behandlung von chronischen schmerzen, cerebralen exzitotoxizitätsbedingten störungen und kardialen arrhythmien |
-
2004
- 2004-07-09 US US10/888,362 patent/US20050027012A1/en not_active Abandoned
- 2004-07-15 WO PCT/EP2004/007849 patent/WO2005007137A2/de not_active Application Discontinuation
- 2004-07-15 EP EP04763241A patent/EP1648423A2/de not_active Withdrawn
- 2004-07-15 CA CA002532485A patent/CA2532485A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1178034A (en) * | 1966-05-10 | 1970-01-14 | Thomae Gmbh Dr K | Hydroxy-Cyclohexylamines |
EP0138020A2 (de) * | 1983-09-17 | 1985-04-24 | Dr. Karl Thomae GmbH | Antiadhäsive Prophylactica und Arzneimittel enthaltend ein sekretolytisch wirksames Benzylaminderivat |
WO2003061642A1 (de) * | 2002-01-25 | 2003-07-31 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Verwendung von ambroxol zur behandlung von chronischen schmerzen, cerebralen exzitotoxizitätsbedingten störungen und kardialen arrhythmien |
Non-Patent Citations (2)
Title |
---|
"AMBROXOL BEI HALSSCHMERZEN" DEUTSCHE APOTHEKER ZEITUNG, DEUTSCHER APOTHEKER ZEITUNG, STUTTGART, DE, Bd. 142, Nr. 17, 25. April 2002 (2002-04-25), Seiten 45-47, XP001147779 ISSN: 0011-9857 * |
ROTE LISTE SERVICE GMBH (ED): "Rote Liste 2002" 2002, ROTE LISTE 2002. ARZNEIMITTELVERZEICHNIS FUER DEUTSCHLAND (EINSCHLIESLICH EU - ZULASSUNGEN UND BESTIMMTER MEDIZINPRODUKTE), AULENDORF : EDITIO CANTOR, DE, PAGE(S) 5389 , XP002247690 ISBN: 3-87193-252-3 24190 Mucosolvan (TM) Filmtabletten 60 mg * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10202383B2 (en) | 2002-08-21 | 2019-02-12 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9556175B2 (en) | 2002-08-21 | 2017-01-31 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions |
US9751855B2 (en) | 2004-11-05 | 2017-09-05 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US11919903B2 (en) | 2006-05-04 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9815837B2 (en) | 2006-05-04 | 2017-11-14 | Boehringer Ingelheim International Gmbh | Polymorphs |
US11291668B2 (en) | 2006-05-04 | 2022-04-05 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US11084819B2 (en) | 2006-05-04 | 2021-08-10 | Boehringer Ingelheim International Gmbh | Polymorphs |
US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9493462B2 (en) | 2006-05-04 | 2016-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US10973827B2 (en) | 2008-04-03 | 2021-04-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9603851B2 (en) | 2010-05-05 | 2017-03-28 | Boehringer Ingelheim International Gmbh | Combination therapy |
US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
Also Published As
Publication number | Publication date |
---|---|
US20050027012A1 (en) | 2005-02-03 |
WO2005007137A3 (de) | 2005-04-28 |
EP1648423A2 (de) | 2006-04-26 |
WO2005007137A8 (de) | 2006-09-21 |
CA2532485A1 (en) | 2005-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005007137A2 (de) | Ambroxolhaltige tabletten | |
DE69730834T2 (de) | Verfahren zur herstellung von festen oralen dosierungsformen von valsartan | |
DE69820287T2 (de) | Pharmazeutische Zubereitung, die Chlodronat als Wirkstoff und silicifizierte mikrokristalline Cellulose als Exipienten umfasst | |
EP1762230B2 (de) | Filmtablette oder Granulat enthaltend ein Pyridylpyrimidin | |
EP2477660B1 (de) | Pharmazeutische zusammensetzung mit den wirkstoffen metformin und sitagliptin oder vildagliptin | |
EP1865921B1 (de) | Pharmazeutische zubereitung von n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamid | |
EP1001757A1 (de) | Schnell wirksames analgeticum | |
EP2595607A2 (de) | Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer | |
DE4001622A1 (de) | Orale arzneimittelformen von pimobendan | |
DE4303846A1 (de) | Verfahren zur Herstellung einer S-Ibuprofen enthaltenden Tablette | |
DE602004005734T2 (de) | Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung | |
DE69930621T2 (de) | Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung | |
DE102004028940A1 (de) | Oral zerfallende pharmazeutische Zusammensetzung, die Risperidon enthält | |
DE102006017896A1 (de) | Leflunomid enthaltende pharmazeutische Zusammensetzungen | |
DE10360086A1 (de) | Ambroxolhaltige Tabletten | |
DE102021119130A1 (de) | Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure | |
EP1408943B1 (de) | Arzneimittelformulierung enthaltend einen ltb4 antagonisten und einen netzmittel | |
EP1886674B1 (de) | Pharmazeutische Zusammensetzung enthaltend Nebivolol | |
EP3593792A1 (de) | Pharmazeutische zusammensetzung umfassend 6-(4-chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizin-5-yl-essigsäurecholinsalz | |
EP2143425A1 (de) | Direktverpresste Aliskiren-Tabletten | |
EP1850834B1 (de) | Filmtabletten enthaltend ibuprofen-lysinat | |
DE10353832A1 (de) | Feste pharmazeutische Zubereitungsform | |
WO2002064124A2 (de) | Arzneimittelformulierung die einen muskarinischen agonisten enthält | |
WO2005023223A2 (de) | Oral zu applizierende darreichungsform für schwerlösliche saure und amphotere wirkstoffe | |
EP1686965A2 (de) | Feste pharmazeutische zubereitungsform |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004763241 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2532485 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006519877 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004763241 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004763241 Country of ref document: EP |